Dr. Reddy's Laboratories unveils Chlorthalidone Tablets, USP in the US market
28 November 2018 -

Pharmaceutical company Dr. Reddy's Laboratories Ltd (NSE:DRREDDY) (NYSE:RDY) Wednesday reported the availability of Chlorthalidone Tablets USP in 25 mg and 50 mg.

The company added the Chlorthalidone Tablets USP in 25 mg and 50 mg is the therapeutic equivalent generic version of the US Food and Drug Administration (USFDA) approved Hygroton (chlorthalidone) Tablets.

For the most recent 12 months ending in September 2018, the Hygroton brand and generic had US sales of approximately USD122m MAT, according to IMS Health.

Additionally, the company's Chlorthalidone Tablets, USP are available in 25 mg tablets in the bottle-count sizes of 100 and 1000, and 50 mg tablets in the bottle-count size of 100.

According to the company, Chlorthalidone is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. It has been found useful in edema due to various forms of renal dysfunction, nephrotic syndrome, acute glomerulonephritis and chronic renal failure.